Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

BACKGROUND. Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We...

詳細記述

保存先:
書誌詳細
出版年:Prostate
主要な著者: Armstrong, Andrew J., Humeniuk, Michael S., Healy, Patrick, Szmulewitz, Russell, Winters, Carolyn, Kephart, Julie, Harrison, Michael R., Martinez, Elia, Mundy, Kelly, Halabi, Susan, George, Daniel
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6309626/
https://ncbi.nlm.nih.gov/pubmed/27862097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23277
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料